Search

everythinglearnresearchcommunity

for

Search:↓

Creatine may increase DHT levels, potentially causing symptoms like acne, oily hair, and hair shedding. Users report mixed experiences, with some avoiding creatine due to hair loss concerns and others seeing no impact.

Biotin is being misleadingly marketed as a primary treatment for androgenic alopecia, overshadowing more effective treatments like finasteride and minoxidil. There is a call for increased awareness and accountability to prevent misinformation.

The conclusion of the conversation is that the user should consider using treatments such as finasteride, minoxidil, and RU58841 to potentially reverse their hair loss. Other suggestions include using hair loss concealers and maintaining a healthy diet.

Gym and creatine can cause hair loss by increasing testosterone and androgenic activity. DHT blockers may help some, while others need androgen suppression with topical AA like RU or Pyri.

The user stopped using finasteride and RU58841 and is considering CB-03-01 for androgenic alopecia but is concerned about the cost and effectiveness, especially at a lower dose than in clinical trials. They are also using minoxidil, micro-needling, and nizoral shampoo but are unsure about the correct application method for CB-03-01.

An 18-year-old experiencing hair loss seeks a finasteride prescription but faces skepticism from doctors who only recommend vitamins. A suggestion is made to consult a dermatologist for a proper diagnosis and potential treatment with finasteride or minoxidil.

Belgium disagrees with the EMA and does not authorize the 1 mg oral form of finasteride for androgenic alopecia, citing a negative benefit-risk ratio. Despite this, some individuals in Belgium can still obtain finasteride through prescriptions, and there is debate over its mental health risks versus its benefits for hair loss and other health issues.

Cyclosporine A is discussed as a powerful hair growth stimulant, potentially more effective than minoxidil, but concerns about safety and side effects, including cancer risk, limit its use. The conversation highlights the need for further research and experimentation with topical application, despite its risks.

A doctor advised a 20-year-old to use minoxidil and vitamins for hair loss, avoiding finasteride due to potential permanent side effects. The doctor claimed minoxidil can protect against DHT effects similar to finasteride.

A 20-year-old with anxiety and depression is considering finasteride for hair loss but is worried about potential side effects. They decide to consult a doctor and consider starting with a low dose, while also exploring topical finasteride as a potentially safer option.

GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.

The conversation is about a user's four-month progress using topical minoxidil for hair loss, with discussions on potential future use of finasteride and natural DHT blockers like saw palmetto and spearmint tea. The user is cautious about oral medications due to past side effects and is exploring natural alternatives.

RU58841 is debated for hair regrowth, with some users reporting no benefits and potential side effects, while others claim success when combined with dutasteride. Many suggest safer, well-researched treatments like finasteride and minoxidil for hair loss management.

Finasteride and dutasteride are discussed for hair loss, with concerns about their effects on neurosteroids and potential side effects like depression. Alternatives like topical estrogen and lifestyle changes are considered, with varying opinions on mental health and hair regrowth.

The conversation discusses why there are no FDA-approved NSAAs like RU58841 on the market, despite their potential superiority to 5AR inhibitors like finasteride. It explores the effectiveness of treatments like Minoxidil, finasteride, and RU58841 for hair loss.

The conversation lists hair loss treatments including finasteride, dutasteride, RU58841, pyrilutamide, breezula, and fluridil, and suggests ketoconazole as another option. Some users warn against using certain treatments like cyproterone acetate, bicalutamide, and spironolactone due to their strong anti-androgen effects and potential impact on masculinity.

The conversation is about the prevalence of baldness among young men and the potential factors contributing to it. Specific treatments mentioned include minoxidil and finasteride.

Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.

Creatine does not directly cause hair loss but may increase DHT levels, potentially worsening hair loss in those predisposed to male pattern baldness. Users have mixed experiences, with some reporting increased shedding and others seeing no effect.

Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.

The availability of Topical Dutasteride, a potential treatment for hair loss, which can be purchased without prescription from MinoxidilMax. Other treatments discussed include Topical Finasteride and PRP injections, with discussion around dosage, efficacy, side-effects and safety.

The conversation discusses hair cloning trials expected to start in 2020-2021 and mentions concerns about potential delays due to the Coronavirus. Treatments like Minoxidil, finasteride, and RU58841 are referenced.

Hair follicle regenerative therapy is being developed, with clinical trials planned in Japan, potentially allowing for hair cloning and eliminating the need for treatments like finasteride. If successful, the treatment could be available in Japan by 2025, but widespread access and affordability may take longer.

Minoxidil may inhibit androgen receptors and affect hormonal pathways, potentially explaining its effectiveness in treating androgenetic alopecia (AGA). Users discuss its varying effectiveness on scalp versus facial hair and note fewer side effects with topical use compared to oral.

Creatine may worsen hair loss in some, especially with androgenic alopecia, but evidence is mixed. Some users experience no hair loss when using creatine with minoxidil and finasteride, while others notice increased shedding.

Finasteride may decrease free testosterone by increasing SHBG, potentially causing side effects like reduced libido and hormonal changes. Some find it effective for hair loss, while others experience negative effects.

Creatine may increase scalp DHT without affecting serum DHT, potentially speeding up male pattern baldness (MPB) for those genetically prone. Treatments mentioned include Minoxidil, finasteride, and RU58841.

The conversation discusses using verteporfin for hair regrowth and minimizing scarring after hair transplants. Some individuals plan to self-administer verteporfin, potentially in combination with microneedling, as an alternative to hair transplants.

Clascoterone cream was submitted for review to Health Canada in August 2022, with hopes of approval within 3-6 months. It may potentially enhance finasteride's effects for hair loss treatment.

A woman experiencing hair loss and facial hair growth suspects PCOS or androgenic alopecia and is considering treatments like Rogaine, but is concerned about the cost. She has tried various hair care methods and is awaiting a hormone doctor appointment, while others suggest she may have a hormonal imbalance and recommend seeing a gynecologist or trying cheaper versions of Rogaine.